Davis Todd C purchased $1,000K of PTHS
Davis Todd C purchased 35,948 shares of Pelthos Therapeutics Inc. (PTHS) at an average of $27.82 ($27.80–$28.73, $1.00M total) across 2 trades on 2026-06-11.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase details (shares, dates, prices, post-transaction holdings).
Market read
Traders may monitor for follow-through, but the filing alone does not change the company’s fundamentals.
What to watch
Transaction size is meaningful but not large enough to imply a strategic shift; absence of 10b5-1 does not guarantee conviction or timing advantage.
Background
The article is a SEC Form 4 insider transaction disclosure for Pelthos Therapeutics Inc.
Ticker impact
Pelthos Therapeutics director Davis Todd C filed an open-market purchase of 35,948 shares at ~$27.82 on 2026-06-11.
Likely limited near-term impact; any effect is more sentiment/positioning than valuation re-rating.
The disclosure is a Form 4 insider transaction with no accompanying operational, clinical, or financial update; 10b5-1 is stated as not pre-arranged, but the article provides no new company-specific fundamentals.
Market effects
No sector-level read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine diversification or personal liquidity planning; without follow-on fundamental news, price reaction may fade.
Key entities
- issuerPelthos Therapeutics Inc.
Subject of the SEC Form 4 insider transaction disclosure.
- insiderDavis Todd C
Director who purchased 35,948 shares across two trades on 2026-06-11.
